Trial NCT01465815

View at ClinicalTrials.gov 
Org. Study IDs: 6901 (5466)
Secondary IDs: NCI-2011-01225

Last trial update was posted on 2014-11-19

MeSH Interventions

Erlotinib Hydrochloride

MeSH Conditions

Carcinoma Carcinoma, Squamous Cell Recurrence

Other Conditions

Recurrent Skin Cancer Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity Squamous Cell Carcinoma of the Skin Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity

Stopping Reasons

Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906 in other oncology studies was determined to be unfavorable.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID